Marksans Pharma Ltd. — Investor Relations & Filings
Marksans Pharma Ltd. specializes in the research, development, and large-scale manufacturing of generic formulations. The company’s therapeutic focus spans pain management, cardiovascular health, central nervous system disorders, anti-diabetics, and gastrointestinal treatments. Its product portfolio includes diverse delivery systems such as solid orals, soft gelatin capsules, and liquid formulations, serving both the over-the-counter and prescription markets. The organization operates advanced manufacturing facilities compliant with international regulatory standards, facilitating a robust supply chain across major global markets including North America, Europe, and Australia. By integrating comprehensive research and development with efficient production processes, the company provides a broad range of high-quality, cost-effective medicinal products to a global patient base.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-09 | English | |
| Press Release | 2026-04-01 | English | |
| Trading Window | 2026-03-26 | English | |
| Copy of Newspaper Publication | 2026-03-12 | English | |
| General Updates | 2026-03-11 | English | |
| General Updates | 2026-03-10 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 42169802 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-09 | English | ||
| 42178891 | Press Release | 2026-04-01 | English | ||
| 42170668 | Trading Window | 2026-03-26 | English | ||
| 42166032 | Copy of Newspaper Publication | 2026-03-12 | English | ||
| 42171933 | General Updates | 2026-03-11 | English | ||
| 42178511 | General Updates | 2026-03-10 | English | ||
| 42183952 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-12 | English | ||
| 42181842 | Press Release | 2026-02-05 | English | ||
| 42182307 | Investor Presentation | 2026-02-05 | English | ||
| 42183229 | Outcome of Board Meeting | 2026-02-05 | English | ||
| 42208443 | General Updates | 2026-01-27 | English | ||
| 42167857 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-01-22 | English | ||
| 42218568 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-01-13 | English | ||
|
2025
2 filings
| |||||
| 42251983 | Trading Window | 2025-12-26 | English | ||
| 42251702 | Analysts/Institutional Investor Meet/Con. Call Updates | 2025-11-21 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
89bio, Inc.
Clinical-stage biopharma developing therapies for liver and…
|
ETNB | US | Manufacturing |
|
Aardvark Therapeutics, Inc.
Clinical-stage biopharma developing therapeutics for hunger…
|
AARD | US | Manufacturing |
|
Aarey Drugs & Pharmaceuticals Ltd
Manufactures APIs and chemical intermediates for global pha…
|
AAREYDRUGS | IN | Manufacturing |
|
Aarti Drugs Limited
Produces APIs, pharma intermediates, and specialty chemical…
|
AARTIDRUGS | IN | Manufacturing |
|
Aarti Pharmalabs Limited
Manufacturer of APIs, intermediates, and xanthines with glo…
|
AARTIPHARM | IN | Manufacturing |
|
AAYUSH WELLNESS LIMITED
Develops and markets herbal formulations, supplements, and …
|
539528 | IN | Manufacturing |
|
Ab&B Bio-Tech CO., LTD. JS
Biopharmaceutical company engaged in the R&D and commercial…
|
2627 | HK | Manufacturing |
|
Abbisko Cayman Limited
Clinical-stage biopharma focused on discovering and develop…
|
2256 | KY | Manufacturing |
|
Abbott India Ltd.
Provides pharmaceutical solutions in gastroenterology, card…
|
ABBOTINDIA | IN | Manufacturing |
|
ABBOTT LABORATORIES
Global healthcare company in medical devices, diagnostics, …
|
ABT | US | Manufacturing |
Marksans Pharma Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/62142/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=62142 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=62142 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=62142 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 62142}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Marksans Pharma Ltd. (id: 62142)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.